How do scientists develop new treatments for disease? With Gleevec, a remarkable cancer drug, the approach was to target the disease at the cellular and subcellular level. When people say Gleevec ...

Nonadherence to Gleevec in GIST patients is common, with cognitive functioning, TDM, and social support as key indicators. A machine learning model using 64 covariates identified 19 significant ...

Chronic myeloid leukaemia (CML) blockbuster Gleevec has been badly hit by generic competition in the US, revenues falling 30% to $834 million in the period. This decline will continue, with ...